Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

Owen O'Connor, John Wright, Craig H. Moskowitz, Jamie Muzzy, Barbara MacGregor-Cortelli, Paul Hamlin, David Straus, Elizabeth Trehu, David P. Schenkein, Andrew D. Zelenetz

Research output: Contribution to journalArticle

Abstract

Dr. O'Connor delivered the following material as a poster at the 2003 American Society of Hematology meeting highlighting results from his work with bortezomib in the treatment of non-Hodgkin's and mantle cell lymphoma. A full publication of his results will appear later this year. Abstract #2346 appears in Blood, Volume 102, issue 11, November 16, 2003. The American Society of Hematology Poster Session "Lymphoma: Treatment and Supportive Care" took place on Sunday, December 7, 2003.

Original languageEnglish (US)
Pages (from-to)S21-22
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume2 Suppl 4
StatePublished - Nov 2004
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.'. Together they form a unique fingerprint.

  • Cite this